Evidence map›Paper›PMID 40275302›Full record

ArticleJournal of translational medicine2025

Potential of CLSPN as a therapeutic target in melanoma: a key player in melanoma progression and tumor microenvironment.

Yongyi Xie, Ruoqi Wang, Mingyuan Xu, Jiashe Chen, Wei Tan, Yanbin Chen, Yun Bai, Nanhui Wu, Fei Wu, Xiaoxiang Xu and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yongyi Xie *Shanghai Skin Disease Hospital, Institute of Dermatology, School of Medicine, Tongji University, Shanghai, China.
Ruoqi Wang *Shanghai Skin Disease Hospital, Institute of Dermatology, School of Medicine, Tongji University, Shanghai, China.
Mingyuan Xu *Shanghai Skin Disease Hospital, Institute of Dermatology, School of Medicine, Tongji University, Shanghai, China.
Jiashe ChenShanghai Skin Disease Hospital, Institute of Dermatology, School of Medicine, Tongji University, Shanghai, China.
Wei TanShanghai Skin Disease Hospital, Institute of Dermatology, School of Medicine, Tongji University, Shanghai, China.
Yanbin ChenShanghai Skin Disease Hospital, Institute of Dermatology, School of Medicine, Tongji University, Shanghai, China.
Yun BaiShanghai Skin Disease Hospital, Institute of Dermatology, School of Medicine, Tongji University, Shanghai, China.
Nanhui WuShanghai Skin Disease Hospital, Institute of Dermatology, School of Medicine, Tongji University, Shanghai, China.
Fei WuShanghai Skin Disease Hospital, Institute of Dermatology, School of Medicine, Tongji University, Shanghai, China.
Xiaoxiang XuShanghai Skin Disease Hospital, Institute of Dermatology, School of Medicine, Tongji University, Shanghai, China.
Xin MaShanghai Skin Disease Hospital, Institute of Dermatology, School of Medicine, Tongji University, Shanghai, China. Nicole.ma@me.com.
Yeqiang LiuShanghai Skin Disease Hospital, Institute of Dermatology, School of Medicine, Tongji University, Shanghai, China. 1500156@tongji.edu.cn.ORCID 0000-0003-3758-1390

Funding

the Natural Science Foundation of Shanghai 23ZR1456100Youth Talent Promotion Project of China Association of Traditional Chinese Medicine (2024-2026) 2024-QNRC2-B04
6 · The paper itself

Abstract

backgroundMelanoma is a highly aggressive form of skin cancer. Despite significant advances in targeted therapies and immunotherapeutic approaches, some patients still have poor response rates, making a deeper understanding of melanoma pathogenesis essential.

methodsThe expression of Claspin (CLSPN), prognosis and immune infiltration in skin cutaneous melanoma patients were analyzed by public databases. Immunohistochemistry was used to validate. Moreover, quantitative real-time polymerase chain reaction analysis, western blot, cell counting kit-8 assay, colony formation assay, flow cytometry, animal experiments, and RNA-seq were applied to explore its biological functions and potential molecular mechanisms of CLSPN in melanoma.

resultsOur results demonstrated that abnormal CLSPN expression was correlated with poor prognosis in melanoma. Meanwhile, CLSPN may promote melanoma growth and progression in vivo and in vitro through IFI44L/JAK/STAT1 signaling. Additionally, CLSPN was associated with negative immune microenvironment in melanoma and may be related to polarization of tumor associated macrophages towards M2-type.

conclusionsThese findings suggest that CLSPN may be a promising new target for melanoma and accelerate personalized therapeutic strategies.

Indexed as

Adaptor Proteins, Signal TransducingDisease ProgressionMelanomaMolecular Targeted TherapySkin NeoplasmsTumor MicroenvironmentAnimalsCell Line, TumorCell ProliferationFemaleGene Expression Regulation, NeoplasticHumansMaleMicePrognosisSignal TransductionAdaptor Proteins, Signal TransducingSTAT1 Transcription FactorCLSPNSKCMTAMsTumor immunological microenvironment

Identifiers

PMID40275302
PMCPMC12020306

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.